View Future GrowthRadnostix 과거 순이익 실적과거 기준 점검 0/6Radnostix 의 수입은 연평균 -48.5%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 3.8%의 비율로 감소했습니다. 매출은 연평균 9.6%의 비율로 증가해 왔습니다.핵심 정보-48.48%순이익 성장률-50.77%주당순이익(EPS) 성장률Life Sciences 산업 성장률21.51%매출 성장률9.62%자기자본이익률-24.59%순이익률-6.95%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 16Radnostix, Inc. announced delayed 10-Q filingOn 05/15/2026, Radnostix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 20International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.공시 • May 19International Isotopes Inc., Annual General Meeting, Jul 10, 2025International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United States공시 • May 01International Isotopes Inc., Annual General Meeting, Jul 10, 2024International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting.공시 • Jul 21+ 1 more updateInternational Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the BoardThe Board of International Isotopes Inc. appointed Mr. Shahe Bagerdjian to serve as a member of the Board, effective immediately. Shahe Bagerdjian, current President of INIS.공시 • Jun 22International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc.International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc. on June 21, 2023. International Isotopes Inc. (OTCPK:INIS) completed the acquisition of Nuclear lung ventilation product line from Amici Inc. on June 21, 2023.공시 • May 25International Isotopes Inc., Annual General Meeting, Jul 12, 2023International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting.공시 • May 09International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective ImmediatelyInternational Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.공시 • May 03International Isotopes Inc., Annual General Meeting, Jun 12, 2022International Isotopes Inc., Annual General Meeting, Jun 12, 2022, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To consider and discuss about electing 3 directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve the compensation of named executive officers; to approve an amendment to Restated Certificate of Formation, as amended, to effect a reverse stock split of the outstanding shares of common stock by a ratio of not less than 1-for-20 and not more than 1-for-150 at any time, with the exact ratio to be set at a whole number within this range by the Board of Directors in its sole discretion; to consider any other business that may properly come before the Annual Meeting; and thereof.공시 • Feb 24Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS).Pharmalogic Idaho, LLC entered into an Asset Purchase Agreement to acquire Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) for $4 million on February 10, 2022. The consideration shall be paid in cash on closing. The transaction is subject to the buyer being satisfied with its due diligence review of the purchased assets and the execution of sublease and transitional services agreements. It is expected to close on or around February 18, 2022. David J. Champoux of Pierce Atwood LLP acted as legal advisor to Pharmalogic Idaho, LLC. Melanie G. Rubocki of Perkins Coie LLP acted as legal advisor to International Isotopes Inc. Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) on February 22, 2022.공시 • Dec 30International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, IncAs disclosed in April 2019, International Isotopes Inc. previously entered into a Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc. (Progenics), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.매출 및 비용 세부 내역Radnostix가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:INIS 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2513-18030 Sep 251408030 Jun 251508031 Mar 251408131 Dec 241408130 Sep 241308130 Jun 2412-18131 Mar 2412-18131 Dec 2312-18130 Sep 2312-17030 Jun 2312-17131 Mar 2311-17031 Dec 221107130 Sep 221007130 Jun 221017031 Mar 221016031 Dec 2110-16030 Sep 21916030 Jun 211026031 Mar 21926031 Dec 20926030 Sep 20905030 Jun 209-15031 Mar 209-25031 Dec 199-25030 Sep 199-15030 Jun 1910-25031 Mar 1910-15031 Dec 1810-15030 Sep 1810-14030 Jun 189-35031 Mar 188-35031 Dec 177-45030 Sep 177-35030 Jun 177-24031 Mar 177-24031 Dec 167-24130 Sep 167-24130 Jun 167-24131 Mar 167-23131 Dec 157-23130 Sep 157-23130 Jun 157-130양질의 수익: INIS 은(는) 현재 수익성이 없습니다.이익 마진 증가: INIS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: INIS은 수익성이 없으며 지난 5년 동안 손실이 연평균 48.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 INIS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: INIS은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(3.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: INIS는 현재 수익성이 없으므로 자본 수익률이 음수(-24.59%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:15종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Radnostix, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mauro SuarezAlliance Global PartnersDavid Matthew KratochvilAlliance Global Partners
공시 • May 16Radnostix, Inc. announced delayed 10-Q filingOn 05/15/2026, Radnostix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 20International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.
공시 • May 19International Isotopes Inc., Annual General Meeting, Jul 10, 2025International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United States
공시 • May 01International Isotopes Inc., Annual General Meeting, Jul 10, 2024International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting.
공시 • Jul 21+ 1 more updateInternational Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the BoardThe Board of International Isotopes Inc. appointed Mr. Shahe Bagerdjian to serve as a member of the Board, effective immediately. Shahe Bagerdjian, current President of INIS.
공시 • Jun 22International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc.International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc. on June 21, 2023. International Isotopes Inc. (OTCPK:INIS) completed the acquisition of Nuclear lung ventilation product line from Amici Inc. on June 21, 2023.
공시 • May 25International Isotopes Inc., Annual General Meeting, Jul 12, 2023International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting.
공시 • May 09International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective ImmediatelyInternational Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.
공시 • May 03International Isotopes Inc., Annual General Meeting, Jun 12, 2022International Isotopes Inc., Annual General Meeting, Jun 12, 2022, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To consider and discuss about electing 3 directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve the compensation of named executive officers; to approve an amendment to Restated Certificate of Formation, as amended, to effect a reverse stock split of the outstanding shares of common stock by a ratio of not less than 1-for-20 and not more than 1-for-150 at any time, with the exact ratio to be set at a whole number within this range by the Board of Directors in its sole discretion; to consider any other business that may properly come before the Annual Meeting; and thereof.
공시 • Feb 24Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS).Pharmalogic Idaho, LLC entered into an Asset Purchase Agreement to acquire Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) for $4 million on February 10, 2022. The consideration shall be paid in cash on closing. The transaction is subject to the buyer being satisfied with its due diligence review of the purchased assets and the execution of sublease and transitional services agreements. It is expected to close on or around February 18, 2022. David J. Champoux of Pierce Atwood LLP acted as legal advisor to Pharmalogic Idaho, LLC. Melanie G. Rubocki of Perkins Coie LLP acted as legal advisor to International Isotopes Inc. Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) on February 22, 2022.
공시 • Dec 30International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, IncAs disclosed in April 2019, International Isotopes Inc. previously entered into a Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc. (Progenics), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.